William Blair initiated coverage on Tenax Therapeutics
$TENX
Biotechnology: Pharmaceutical Preparations
Health Care
William Blair initiated coverage of Tenax Therapeutics with a rating of Outperform
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/17/2026 | $35.00 | Overweight | Cantor Fitzgerald |
| 9/8/2025 | $20.00 | Overweight | Piper Sandler |
| 10/24/2024 | $16.00 | Outperform | Leerink Partners |
| 10/14/2024 | $16.00 | Buy | Guggenheim |
| 9/30/2024 | Outperform | William Blair |
4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)
3 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)
4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)
8-K - TENAX THERAPEUTICS, INC. (0000034956) (Filer)
SCHEDULE 13G/A - TENAX THERAPEUTICS, INC. (0000034956) (Subject)
SCHEDULE 13G/A - TENAX THERAPEUTICS, INC. (0000034956) (Subject)
4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)
4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)
4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)
Cantor Fitzgerald initiated coverage of Tenax Therapeutics with a rating of Overweight and set a new price target of $35.00
Piper Sandler initiated coverage of Tenax Therapeutics with a rating of Overweight and set a new price target of $20.00
Leerink Partners initiated coverage of Tenax Therapeutics with a rating of Outperform and set a new price target of $16.00
On track to report topline data from Phase 3 LEVEL study of TNX-103 in third quarter of 2026 Global Phase 3 LEVEL-2 clinical trial ongoing, enrollment completion anticipated by end of 2027 Strengthened leadership team with appointments of Thomas Staab as Chief Financial Officer and Timothy Healey, MBA, as Chief Commercial Officer CHAPEL HILL, N.C., May 12, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX) ("Tenax" or "Tenax Therapeutics" or the "Company"), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, reported today financial results for the quarter ended March 31, 2026 and provided an update on its
CHAPEL HILL, N.C., May 08, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX) ("Tenax" or "Tenax Therapeutics" or the "Company"), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today announced it has awarded or will award inducement option awards between April 28, 2026 and June 1, 2026 as material inducements to the employment of four non-executive individuals newly hired by the Company in various clinical operations, medical, product development, and commercial roles. The employees received or will receive, in the aggregate, non-qualified stock options to purchase 657,500 shares of the Company's common
CHAPEL HILL, N.C., May 04, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX) ("Tenax" or "Tenax Therapeutics" or the "Company"), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, announced today the appointment of Timothy Healey, MBA, as Chief Commercial Officer (CCO), effective immediately. Mr. Healey is a proven commercial leader who has led several successful drug launches and joins Tenax to oversee its global commercial strategy. "Tim is a transformational commercial leader with a proven ability to translate complex science into successful product launches," said Chris Giordano, President and Chief Exe
On track to report topline data from Phase 3 LEVEL study of TNX-103 in third quarter of 2026 Global Phase 3 LEVEL-2 clinical trial ongoing, enrollment completion anticipated by end of 2027 Strengthened leadership team with appointments of Thomas Staab as Chief Financial Officer and Timothy Healey, MBA, as Chief Commercial Officer CHAPEL HILL, N.C., May 12, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX) ("Tenax" or "Tenax Therapeutics" or the "Company"), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, reported today financial results for the quarter ended March 31, 2026 and provided an update on its
CHAPEL HILL, N.C., May 04, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX) ("Tenax" or "Tenax Therapeutics" or the "Company"), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, announced today the appointment of Timothy Healey, MBA, as Chief Commercial Officer (CCO), effective immediately. Mr. Healey is a proven commercial leader who has led several successful drug launches and joins Tenax to oversee its global commercial strategy. "Tim is a transformational commercial leader with a proven ability to translate complex science into successful product launches," said Chris Giordano, President and Chief Exe
Mr. Staab has over 25 years of financial and executive experience across the healthcare industry CHAPEL HILL, N.C., April 22, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX) ("Tenax" or "Tenax Therapeutics" or the "Company"), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, announced today the appointment of Thomas R. Staab, II as Chief Financial Officer (CFO), effective May 11, 2026. Mr. Staab brings over 25 years of leadership experience across management and corporate finance roles in the healthcare industry. He will replace Thomas McGauley, who has served as interim CFO since December 2024. "Tom br
Phase 3 LEVEL Study Ongoing, Enrollment Completion (230 Patients) Expected in First Half of 2026, with Topline Data Expected in Second Half of 2026 On Track to Initiate Second Phase 3 Study, LEVEL-2, in 2025 Tenax to Host Virtual KOL Call Tomorrow, Thursday, November 13, 2025 at 4:30 p.m. ET CHAPEL HILL, N.C., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX) ("Tenax" or "Tenax Therapeutics" or the "Company"), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today reported financial results for the quarter ended September 30, 2025 and provided an update on its recent corporate progress. "We c
Tenax Therapeutics, Inc. (NASDAQ:TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today reported financial results for the first quarter of 2021 and provided a business update. "Having completed the merger with PHPrecisionMed Inc., we now have product development programs in group one and group two pulmonary hypertension patients," stated Anthony DiTonno, Chief Executive Officer of Tenax, "which represent more than 70% of the overall market. "We have begun the open label transition study using the oral formulation of Levosimendan, which was recently acq
MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing, and commercializing products for the critical care market, today announced the acquisition of PH Precision Med (PHPM), a privately-held clinical stage biotech company focused on developing imatinib for the treatment of pulmonary arterial hypertension (PAH). The FDA has granted Orphan Drug Designation for imatinib for the treatment of PAH, an indication with a high unmet medical need. The acquisition expands Tenax’s pulmonary hypertension pipeline with the addition of imatinib, a Phase 3 ready candidate. Imatinib is a tyrosine kinase i
SC 13G - TENAX THERAPEUTICS, INC. (0000034956) (Subject)
SC 13G/A - TENAX THERAPEUTICS, INC. (0000034956) (Subject)
SC 13G/A - TENAX THERAPEUTICS, INC. (0000034956) (Subject)